An observational study in COPD Exacerbation, sponsored by Samsung Medical Center. Enrolling by invitation at 1 site in Korea, Republic of. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-10-18.
Sponsored by Samsung Medical Center · Observational
Among 148 studies in Pulmonary Disease, Chronic Obstructive with a site in Korea, Republic of — 19 open to participants now, 26 under way, 7 of them phase 3. Pulmonary Disease, Chronic Obstructive · Korea, Republic of.
Among the 148 studies in Pulmonary Disease, Chronic Obstructive with a site in Korea, Republic of, this one is the 25th largest by planned enrollment of the 32 observational ones that give a count, is one of 8 that started in 2017, is one of 32 observational ones, reaches primary completion later than 4 of the 25 other live ones, and was the 96th registered.
5,520 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →19 of the 148 studies in Pulmonary Disease, Chronic Obstructive with a site in Korea, Republic of are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
Eli Lilly and Company · Sites in Korea, Republic of, United States, Argentina and 15 more countries
Ages 40–75
Samsung Medical Center · Sites in Korea, Republic of
Ages 19–100
Pfizer · Sites in Korea, Republic of, United States, Argentina and 15 more countries
Ages 35–80
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 555 Pulmonary Disease, Chronic Obstructive studies recruiting now, 305 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 87 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
148 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 24 · Phase 3 73 · Phase 4 7
First in 2002; this study’s year is marked. 8 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 86 is below the median of 158 across 1,497 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 657 across the 115 interventional studies, 432 across the 32 observational. Of the 111 that completed or were terminated, 71 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 148 have an industry lead sponsor. The 10 most frequent:
Samsung Medical Center is the lead sponsor of 1,011 studies on the registry; 152 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Samsung Medical Center has 5 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
7 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07712016Seoul National UniversityMuco-active Agent Use and Clinical Outcomes After Lung Cancer Diagnosis in Chronic Obstructive Pulmonary Disease | 2026-12-31 |
| NCT07638176Samsung Medical CenterEffect of Individualized Positive End-expiratory Pressure (PEEP) in Patients Who Have an Intrinsic PEEP During One-lung Ventilation | 2027-05-31 |
| NCT07570394AstraZenecaBREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA | 2027-07-31 |
| NCT07082738AstraZenecaA Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | 2027-08-31 |
Among the 148 studies in Pulmonary Disease, Chronic Obstructive with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients who are suffering from Chronic Obstructive Pulmonary Disease (COPD) had a decreased level of physical activity which is consequentially related to another acute exacerbation event. In this study, we selected patients from those who were admitted for acute exacerbation of COPD, evaluated physical activity by accelerometer (wearable multisensory armband devices) to find out the correlation between physical activity in COPD acute exacerbation patients.
Based on COPD patients who visited Samsung medical center.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Re admission rate after COPD acute exacerbation
Time frame: 13 weeks
Started Nov 2017 (actual). Primary completion is estimated for Nov 2025, 96 months after the start.
Of 466 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 64. This study's planned 96 months is above that.
Counting every sponsor, half of 586 studies reached it within 26 months; a quarter within 14 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →